WNT signaling in activated microglia is proinflammatory

GLIA

Volumn 59, Issue 1, 2011, Pages 119-131

  Halleskog, Carina ^a   Mulder, Jan ^b   Dahlström, Jenny ^a   Mackie, Ken ^c   Hortobágyi, Tibor ^d   Tanila, Heikki ^e,f   Kumar Puli, Lakshman ^e   Färber, Katrin ^g   Harkany, Tibor ^a,b   Schulte, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c INDIANA UNIVERSITY   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Aging; Alzheimer's disease; Frizzled; Neurodegeneration; Neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN; BETA CATENIN; DISHEVELLED PROTEIN; FRIZZLED PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; TUMOR NECROSIS FACTOR ALPHA; WNT3A PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CYTOKINE RELEASE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRIZZLED RECEPTORS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICROGLIA; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 78349296382     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21081     Document Type: Article

References (57)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
2. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. 2004. Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196.
3. Boland GM, Perkins G, Hall DJ, Tuan RS. 2004. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93: 1210-1230.
4. Bryja V, Schulte G, Arenas E. 2007. Wnt-3a utilizes a novel low dose and rapid pathway that does not require casein kinase 1-mediated phosphorylation of Dvl to activate β-catenin. Cell Signal 19: 610-616.
5. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F. 2004. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24: 6021-6027.
6. Castelo-Branco G, Wagner J, Rodriguez FJ, Kele J, Sousa K, Rawal N, Pasolli HA, Fuchs E, Kitajewski J, Arenas E. 2003. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a Proc Natl Acad Sci USA 100: 12747-12752.
7. Chacón MA, Varela-Nallar L, Inestrosa NC. 2008. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers. J Cell Physiol 217: 215-227.
8. Cong F, Schweizer L, Varmus H. 2004. Wnt signals across the plasma membrane to activate the β-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 131: 5103-5115.
9. De Ferrari GV, Moon RT. 2006. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25: 7545-7553.
10. De Ferrari GV, Chacón MA, Barría MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC. 2003. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol Psychiatry 8: 195-208.
11. Dinamarca MC, Colombres M, Cerpa W, Bonansco C, Inestrosa NC. 2008. β-Amyloid oligomers affect the structure and function of the postsynaptic region: Role of the Wnt signaling pathway. Neurodegener Dis 5: 149-152.
12. Farfara D, Lifshitz V, Frenkel D. 2008. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 12: 762-780.
13. Ferrari D, Villalba M, Chiozzi P, Falzoni S, Ricciardi-Castagnoli P, Di Virgilio F. 1996. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J Immunol 156: 1531-1539.
14. Garbelli R, Inverardi F, Medici V, Amadeo A, Verderio C, Matteoli M, Frassoni C. 2008. Heterogeneous expression of SNAP-25 in rat and human brain. J Comp Neurol 506: 373-386.
15. 3 receptors in microglia cells. J Neurochem 86: 1051-1054.
16. Hanisch UK. 2002. Microglia as a source and target of cytokines. Glia 40: 140-155.
17. Hanisch UK, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
18. Harkany T, Härtig W, Berghuis P, Dobszay MB, Zilberter Y, Edwards RH, Mackie K, Ernfors P. 2003. Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons. Eur J Neurosci 18: 1979-1992.
19. Hendrickx M, Leyns L. 2008. Non-conventional Frizzled ligands and Wnt receptors. Dev Growth Differ 50: 229-243.
20. Hooper C, Killick R, Lovestone S. 2008. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-1439.
21. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA. 2008. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33: 192-206.
22. Hwang SG, Ryu JH, Kim IC, Jho EH, Jung HC, Kim K, Kim SJ, Chun JS. 2004. Wnt-7a causes loss of differentiated phenotype and inhibits apoptosis of articular chondrocytes via different mechanisms. J Biol Chem 279: 26597-26604.
23. Inestrosa NC, Arenas E. 2010. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11: 77-86.
24. Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M. 2007. Synaptotoxicity in Alzheimer's disease: The Wnt signaling pathway as a molecular target. IUBMB Life 59: 316-321.
25. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13: 159-170.
26. Jin T, George Fantus I, Sun J. 2008. Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of β-catenin. Cell Signal 20: 1697-1704.
27. Kloss CU, Kreutzberg GW, Raivich G. 1997. Proliferation of ramified microglia on an astrocyte monolayer: Characterization of stimulatory and inhibitory cytokines. J Neurosci Res 49: 248-254.
28. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. 1998. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 187: 601-608.
29. Lynch MA. 2009. The multifaceted profile of activated microglia. Mol Neurobiol 40: 139-156.
30. MacDonald BT, Tamai K, He X. 2009. Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev Cell 17: 9-26.
31. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST. 2008. Amyloid-β binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/β-catenin signaling. J Biol Chem 283: 9359-9368.
32. Malaterre J, Ramsay RG, Mantamadiotis T. 2007. Wnt-Frizzled signalling and the many paths to neural development and adult brain homeostasis. Front Biosci 12: 492-506.
33. Martín-Ibañez R, Jenstad M, Berghuis P, Edwards RH, Hioki H, Kaneko T, Mulder J, Canals JM, Ernfors P, Chaudhry FA, Harkany T. 2006. Vesicular glutamate transporter 3 (VGLUT3) identifies spatially segregated excitatory terminals in the rat substantia nigra. Eur J Neurosci 23: 1063-1070.
34. Matteoli M, Pozzi D, Grumelli C, Condliffe SB, Frassoni C, Harkany T, Verderio C. 2009. The synaptic split of SNAP-25: Different roles in glutamatergic and GABAergic neurons? Neuroscience 158: 223-230.
35. Miller KR, Streit WJ. 2007. The effects of aging, injury and disease on microglial function: A case for cellular senescence. Neuron Glia Biol 3: 245-253.
36. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fülöp L, Penke B, Zilberter Y, Harkany T, Pitkänen A, Tanila H. 2009. Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29: 3453-3462.
37. Morales I, Farías G, Maccioni RB. 2010. Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 17: 202-204.
38. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. 2007. Modulation of immune response by head injury. Injury 38: 1392-1400.
39. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF. 1999. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019.
40. Pereira CP, Bachli EB, Schoedon G. 2009. The wnt pathway: A macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep 11: 236-242.
41. Perry VH, Cunningham C, Boche D. 2002. Atypical inflammation in the central nervous system in prion disease. Curr Opin Neurol 15: 349-354.
42. Phiel CJ, Wilson CA, Lee VM, Klein PS. 2003. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423: 435-439.
43. Pocock JM, Kettenmann H. 2007. Neurotransmitter receptors on microglia. Trends Neurosci 30: 527-535.
44. Prinz M, Kann O, Draheim HJ, Schumann RR, Kettenmann H, Weber JR, Hanisch UK. 1999. Microglial activation by components of gram-positive and -negative bacteria: Distinct and common routes to the induction of ion channels and cytokines. J Neuropathol Exp Neurol 58: 1078-1089.
45. Querfurth HW, LaFerla FM. 2010. Alzheimer's disease. N Engl J Med 362: 329-344.
46. Rivest S. 2009. Regulation of innate immune responses in the brain. Nat Rev Immunol 9: 429-439.
47. Schnell SA, Staines WA, Wessendorf MW. 1999. Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 47: 719-730.
48. Schulte G. IUPHAR nomenclature report: The class frizzled receptors. Pharmacol Rev (in press).
49. Schulte G, Bryja V. 2007. The Frizzled family of unconventional G-protein-coupled receptors. Trends Pharmacol Sci 28: 518-525.
50. Shimizu H, Julius MA, Giarré M, Zheng Z, Brown AM, Kitajewski J. 1997. Transformation by Wnt family proteins correlates with regulation of β-catenin. Cell Growth Differ 8: 1349-1358.
51. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P. 2007. Imaging microglial activation in Huntington's disease. Brain Res Bull 72: 148-151.
52. Tansey MG, Goldberg MS. 2010. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518.
53. Toledo EM, Inestrosa NC. 2009. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15: 272-285.
54. 2 receptors. Science 310: 329-332.
55. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. 2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405.
56. Weinstein JR, Koerner IP, Möller T. 2010. Microglia in ischemic brain injury. Future Neurol 5: 227-246.
57. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, Nusse R. 2003. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423: 448-452.